Successful Management of Gamma-hydroxybutyrate (GHB) Withdrawal Using Baclofen as a Standalone Therapy: A Case Report. Issue 5 (September 2019)

• Record Type: Journal Article
• Authors: Habibian, Sonia; Ahamad, Keith; McLean, Mark; Socias, Maria Eugenia
• Is Part Of: Journal of addiction medicine. Volume 13:Issue 5(2019)
• Publication Date: 2019-09
• Subjects: 1, 4-butanediol -- baclofen -- detoxification -- gama-hydroxybutyrate -- gamma butyrolanctone -- withdrawal; Substance abuse -- Periodicals; Substance abuse -- Treatment -- Periodicals; Substance-Related Disorders -- Periodicals; 616.86005
• DOI: 10.1097/ADM.0000000000000514
• Languages: English
• ISSNs: 1932-0620

Abstract

Abstract : Background: Gamma-hydroxybutyrate (GHB)—a GABA-B agonist—can lead to a use disorder, and a withdrawal syndrome similar to that of alcohol. At present, evidence is lacking for how to best manage GHB withdrawal, and often clinicians rely on alcohol withdrawal management approaches, using medications like benzodiazepines (BZD). However, BZD doses needed to control GHB withdrawal symptoms are typically much higher than those required for alcohol, posing significant safety risks. Novel approaches include the use of baclofen as an adjunct to BZD, allowing reductions in BZD requirements. While the use of baclofen as monotherapy may result in even greater risk reductions, research to support this approach is limited. Case: We present a case of a 26-year-old female with severe GHB use disorder and history of severe withdrawal symptoms, whose withdrawal was successfully, managed using baclofen alone. Conclusion: In keeping with other case reports, baclofen appears to have potential to be used in the management of GHB withdrawal. Here, we presented a case of severe GHB withdrawal which was managed solely by baclofen. Clinical research is needed to evaluate baclofen's potential as a standalone treatment for GHB withdrawal.